• Join
  • Login
  • Contact

Search abstracts

The growing analytical toolbox for complex drugs: Assessment of NBCD bioequivalence

  • At: Stockholm (Sweden) (2017)
  • Type: Presentation
  • By: MCNEIL, Scott (Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Frederick, United States)
  • Co-author(s): Scott Mcneil: Nanotechnology Characterization Laboratory Cancer Research Technology Program -Leidos Biomedical Research, Inc , Frederick National Lab, Frederick, United States
  • Abstract:

    Nanomedicines, a subclass of NBCDs, often demonstrate unique therapeutic advantages over the legacy formulated drug. By altering the drug’s pharmacokinetic properties, nanomedicines can increase half-life, enhance distribution to target tissues, and decrease off-target toxicity of the API. By definition, nanoscale NBCDs are complex and cannot be


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses